Phase Forward Announces First Quarter Financial Reporting Date for April 27, 2010

WALTHAM, Mass.--(BUSINESS WIRE)-- Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced today that it will release financial results for the quarter ended March 31, 2010 and hold a conference call with investors on Tuesday, April 27, 2010. The Company plans to hold the investor conference call, hosted by Bob Weiler, chairman and chief executive officer, and Chris Menard, senior vice president and chief financial officer, to discuss its first quarter 2010 financial results and its outlook for the second quarter and full year 2010. The call will be held on Tuesday, April 27, 2010, at 5:00 p.m. (EDT).

The investor conference call will be available via live webcast on Phase Forward’s web site at www.phaseforward.com under the tab “Investors.” To participate by telephone, the domestic dial-in number is 888-713-4215 and the international dial-in is 617-213-4867. The access code is 52895202. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PQBYQ3EBK. Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.

The webcast will be available for replay until Thursday, May 27, 2010 on the “Investors” page of Phase Forward’s website.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.



CONTACT:

Public Relations
CHEN PR, Inc
Barbara Heffner, 508-397-1138
[email protected]
or
Investor Relations
ICR
Timothy Dolan, 617-956-6727
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Technology  Data Management  Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  Professional Services  Finance  Research  Science

MEDIA:

Logo
 Logo